» Articles » PMID: 32472951

Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Overview
Journal Oncologist
Specialty Oncology
Date 2020 May 31
PMID 32472951
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Survival after liver resection of hepatocellular carcinoma (HCC) remains poor because of a high incidence of recurrence. We sought to investigate risk factors, patterns, and long-term prognosis among patients with early and late recurrence after liver resection for hepatitis B virus (HBV)-associated HCC.

Methods: Data of consecutive patients undergoing curative resection for HBV-associated HCC were analyzed. According to the time to recurrence after surgery, recurrence was divided into early (≤2 years) and late recurrence (>2 years). Characteristics, patterns of initial recurrence, and postrecurrence survival (PRS) were compared between patients with early and late recurrence. Risk factors of early and late recurrence and predictors of PRS were identified by univariable and multivariable Cox regression analyses.

Results: Among 894 patients, 322 (36.0%) and 282 (31.5%) developed early and late recurrence, respectively. On multivariable analyses, preoperative HBV-DNA >10 copies/mL was associated with both early and late recurrence, whereas postoperative no/irregular antiviral therapy was associated with late recurrence. Compared with patients with late recurrence, patients with early recurrence had a lower proportion of intrahepatic-only recurrence (72.0% vs. 91.1%, p < .001), as well as a lower chance of receiving potentially curative treatments for recurrence (33.9% vs. 50.7%, p < .001) and a worse median PRS (19.1 vs. 37.5 months, p < .001). Multivariable analysis demonstrated that early recurrence was independently associated with worse PRS (hazard ratio, 1.361; 95% confidence interval, 1.094-1.692; p = .006).

Conclusion: Although risk factors associated with early recurrence and late recurrence were different, a high preoperative HBV-DNA load was an independent hepatitis-related risk for both early and late recurrence. Early recurrence was associated with worse postrecurrence survival among patients with recurrence.

Implications For Practice: Liver resection is the main curative treatment for hepatocellular carcinoma (HCC), but postoperative survival remains poor because of high recurrence rates. This study investigated the risk factors and patterns of early and late recurrence and found that a high preoperative hepatitis B virus (HBV) DNA load was an independent hepatitis-related risk factor for both. Early recurrence was also independently associated with worse postrecurrence survival. These data may provide insights into different biological origin and behavior of early versus late recurrence after resection for HBV-associated HCC, which could be helpful to make individualized treatment decision for recurrent HCC, as well as strategies for surveillance recurrence after resection.

Citing Articles

Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China.

Zhang X, Zhang T, Wu F, Li Z, Xiao Z, Yu Z Hepatol Int. 2025; .

PMID: 40063322 DOI: 10.1007/s12072-025-10802-w.


First-Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR: A Case Report.

Jin Z, Zhou F, Wang Z, Li H Cancer Rep (Hoboken). 2025; 8(3):e70136.

PMID: 40035422 PMC: 11877328. DOI: 10.1002/cnr2.70136.


Hepatocellular carcinoma recurrence: Predictors and management.

Abdelhamed W, El-Kassas M Liver Res. 2025; 7(4):321-332.

PMID: 39958776 PMC: 11791921. DOI: 10.1016/j.livres.2023.11.004.


Prognostic Value of the ASAP Score for Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multicenter Analysis of 1,239 Patients.

Yang T, Yin D, Diao Y, Wang M, Wang X, Zeng Y J Clin Exp Hepatol. 2025; 15(3):102497.

PMID: 39917418 PMC: 11795555. DOI: 10.1016/j.jceh.2024.102497.


Therapeutic Potential of Hongjam in A Diethylnitrosamine and Thioacetamide-induced Hepatocellular Carcinoma Mouse Model.

Han Y, Ahn H, Lee D, Song M, Lee S, Jang Y J Cancer Prev. 2025; 29(4):165-174.

PMID: 39790225 PMC: 11706731. DOI: 10.15430/JCP.24.029.


References
1.
Kao J, Chen P, Chen D . Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res. 2010; 108:21-72. DOI: 10.1016/B978-0-12-380888-2.00002-9. View

2.
Pecchi A, Besutti G, De Santis M, Del Giovane C, Nosseir S, Tarantino G . Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree. World J Hepatol. 2015; 7(2):276-84. PMC: 4342610. DOI: 10.4254/wjh.v7.i2.276. View

3.
Zheng J, Chou J, Gonen M, Vachharajani N, Chapman W, Doyle M . Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg. 2017; 266(4):693-701. PMC: 8404085. DOI: 10.1097/SLA.0000000000002360. View

4.
Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M, Ercolani G . Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2008; 16(2):413-22. DOI: 10.1245/s10434-008-0232-4. View

5.
Shah S, Greig P, Gallinger S, Cattral M, Dixon E, Kim R . Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006; 202(2):275-83. DOI: 10.1016/j.jamcollsurg.2005.10.005. View